Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating optic atrophy

An optic nerve atrophy and composition technology, which can be used in drug combinations, nervous system diseases, pharmaceutical formulations, etc., and can solve problems such as difficult treatment, complex etiology, and unsatisfactory curative effects.

Inactive Publication Date: 2017-05-17
JINAN HAOYU QINGTIAN PHARMA TECH CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] Optic atrophy is a common and difficult fundus disease in clinical practice where optic nerve fibers undergo degeneration and conduction dysfunction under the influence of various etiologies, resulting in vision loss or loss.
At present, Western medicine mainly uses drugs for nourishing nerves and drugs for dilating blood vessels and improving circulation, but the curative effect is not satisfactory.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating optic atrophy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Embodiment 1: The pharmaceutical composition and preparation method thereof for the treatment of optic atrophy

[0033] The composition and parts by weight of the raw materials of the pharmaceutical composition for treating optic atrophy are: 28g of pteroside, 1285g of purple teak, 843g of three diamond winds;

[0034] Preparation:

[0035](1) According to the ratio of raw materials, take pteroside, red teak, and three diamonds, mix them evenly, use ethanol with a concentration of 48% by weight as a solvent, and extract by warm soaking at 25°C. The number of extractions is 12 times, each time The extraction time is 20 hours, and the amount of solvent used each time is 63 times of the total weight of the raw material drug, filtered to obtain medicinal residue A and extract A, the extract A recovers ethanol, concentrates to a relative density of 1.14, filters, and the drug solution passes through FU -01 macroporous adsorption resin column, elute with water first, then el...

Embodiment 2

[0038] Embodiment 2: the pharmaceutical composition and preparation method thereof for the treatment of optic atrophy

[0039] The composition and parts by weight of the crude drug of the pharmaceutical composition for treating optic atrophy are: 26g of pteroside, 1290g of purple teak, 840g of three diamond winds;

[0040] Preparation:

[0041] (1) According to the ratio of raw materials, take pteroside, red teak, and three diamonds, mix them evenly, use ethanol with a concentration of 48% by weight as a solvent, and extract by warm soaking at 25°C. The number of extractions is 12 times, each time The extraction time is 20 hours, and the amount of solvent used each time is 63 times of the total weight of the raw material drug, filtered to obtain medicinal residue A and extract A, the extract A recovers ethanol, concentrates to a relative density of 1.14, filters, and the drug solution passes through FU -01 macroporous adsorption resin column, elute with water first, then elut...

Embodiment 3

[0044] Embodiment 3: the pharmaceutical composition and preparation method thereof for the treatment of optic atrophy

[0045] The composition and parts by weight of the raw materials of the pharmaceutical composition for treating optic atrophy are: 30g of pteroside, 1280g of purple teak, 846g of three diamond winds;

[0046] Preparation:

[0047] (1) According to the ratio of raw materials, take pteroside, red teak, and three diamonds, mix them evenly, use ethanol with a concentration of 48% by weight as a solvent, and extract by warm soaking at 25°C. The number of extractions is 12 times, each time The extraction time is 20 hours, and the amount of solvent used each time is 63 times of the total weight of the raw material drug, filtered to obtain medicinal residue A and extract A, the extract A recovers ethanol, concentrates to a relative density of 1.14, filters, and the drug solution passes through FU -01 macroporous adsorption resin column, elute with water first, then e...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition for treating optic atrophy and a preparation method thereof. The pharmaceutical composition is prepared by proportioning trifolirhizin, purple teakwood and Japanese spicebush barks as raw material medicines and can be prepared into various forms according to a conventional preparation process, and is remarkable in curative effect for treating optic atrophy.

Description

technical field [0001] The invention belongs to the technical field of traditional Chinese medicines, and in particular relates to a pharmaceutical composition for treating optic atrophy and a preparation method thereof. Background technique [0002] Optic atrophy is a common and difficult fundus disease in clinical practice where optic nerve fibers undergo degeneration and conduction dysfunction under the influence of various etiologies, resulting in vision loss or loss. . At present, Western medicine mainly uses drugs for nourishing nerves and drugs for dilating blood vessels and improving circulation, but the curative effect is not satisfactory. Ischemia, insufficient oxygen supply, inflammation, or mechanical compression such as tumors in the ascending part of the optic nerve, eye trauma, etc. can cause degeneration of optic ganglion cell axons, and eventually form optic atrophy, which is a sequela. The clinical diagnosis is mainly based on its characteristic changes, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/85A61P27/02A61P25/00A61K31/7048
CPCA61K36/85A61K31/7048A61K36/54A61K2236/333A61K2236/39A61K2236/51A61K2236/55
Inventor 不公告发明人
Owner JINAN HAOYU QINGTIAN PHARMA TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com